BUZZ-Cardiff Oncology plunges after top executives step down

Reuters01-27 21:02
BUZZ-<a href="https://laohu8.com/S/CRDF">Cardiff Oncology</a> plunges after top executives step down

** Shares of drug developer Cardiff Oncology CRDF.O fall 32% to $2 premarket

** Cardiff's CEO and CFO both step down, effective immediately

** Co says board member Mani Mohindru appointed as interim CEO while it searches for replacements

** Separately, CRDF says a mid-stage trial showed that adding its experimental drug, onvansertib, to a standard first‑line chemotherapy regimen improved response rates and delayed disease progression in patients with a hard-to-treat form of colorectal cancer

** Says patients who received the higher 30-milligram dose of onvansertib alongside standard chemotherapy had a 72% response rate, compared with 43% for those on standard treatment alone

** Adds that it plans to launch a larger, late-stage trial later this year

** In 2025, CRDF fell 34%

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment